Small9vege
2021-07-06
Fda approved!
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":157235621,"tweetId":"157235621","gmtCreate":1625582877763,"gmtModify":1633939359629,"author":{"id":3562667296088326,"idStr":"3562667296088326","authorId":3562667296088326,"authorIdStr":"3562667296088326","name":"Small9vege","avatar":"https://static.tigerbbs.com/1d3248be92c07e522220bfdfffd9d0c3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":392,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Fda approved! </p></body></html>","htmlText":"<html><head></head><body><p>Fda approved! </p></body></html>","text":"Fda approved!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/157235621","repostId":2149350420,"repostType":2,"repost":{"id":"2149350420","pubTimestamp":1625572800,"share":"https://www.laohu8.com/m/news/2149350420?lang=&edition=full","pubTime":"2021-07-06 20:00","market":"us","language":"en","title":"Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2149350420","media":"GlobeNewswire","summary":"Sydney, July 06, 2021 (GLOBE NEWSWIRE) -- ASX/Media Release\n\nRegulatory steps completed with the com","content":"<html><body><p>Sydney, July 06, 2021 (GLOBE NEWSWIRE) -- <strong>ASX/Media Release</strong></p>\n<ul>\n<li>Regulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval received in the United States to commence TACTI-003</li>\n<li>Patient recruitment into the trial is expected to begin within this quarter with European and Australian sites expected to follow</li>\n</ul>\n<p><a href=\"https://laohu8.com/S/IMMP\">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (\"<a href=\"https://laohu8.com/S/IMM.AU\">Immutep</a>” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces it has completed all the necessary competent authority steps with the US Food and Drug Administration (FDA) and has received IRB approval to commence its phase IIb TACTI-003 trial in the United States. Patient recruitment for the TACTI-003 trial is expected to begin within this quarter.</p>\n<p>TACTI-003 will evaluate the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”), in combination with MSD’s KEYTRUDA® (pembrolizumab) as a first line therapy in approximately 154 patients with Head and Neck Squamous Cell Carcinoma (HNSCC). It is a randomised, controlled clinical study that will take place across Australia, Europe and the United States of America in up to 35 clinical sites. </p>\n<p>Immutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021. </p>\n<p>Pending approval by the European and Australian competent authorities and ethics committees, Immutep expects to broaden its recruitment sites into these regions. <br/> <br/><strong>Commenting on the start of the TACTI-003 trial, Immutep CSO and CMO Frédéric Triebel said:</strong> “We are delighted to start our new TACTI-003 trial in 1<sup>st</sup> line HNSCC patients to evaluate efti in combination with pembrolizumab vs pembrolizumab monotherapy. Results we reported from this therapeutic combination earlier in June at ASCO in the 2<sup>nd</sup> line setting were robust, with sustained and durable responses. We look forward to deepening these results with a larger group of 1<sup>st</sup> line HNSCC patients in TACTI-003.” </p>\n<p><strong>About TACTI-003</strong><br/>TACTI-003 is a Phase IIb clinical trial in 1st line Head and Neck Squamous Cell Carcinoma (HNSCC). It will evaluate efti in combination with MSD’s KEYTRUDA® (pembrolizumab) as a first line therapy in unresectable recurrent or metastatic HNSCC patients with PD-L1 negative and PD-L1 positive (CPS ≥1) tumors. It will be a randomised, controlled clinical study in approximately 154 first line HNSCC patients and will take place across Australia, Europe and the United States of America in up to 35 clinical sites. </p>\n<p>The study will evaluate the safety and efficacy of efti in combination with pembrolizumab, compared to pembrolizumab alone in 1st line metastatic or recurrent HNSCC patients with PD-L1 positive (CPS ≥1) tumors (cohort A), and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors (CPS <1) (cohort B). According to the current plans, about 130 patients in cohort A will be randomised 1:1 to receive either efti plus pembrolizumab or pembrolizumab alone. Subjects in cohort B (up to 24 patients) will receive a combination of efti and pembrolizumab. </p>\n<p>The primary endpoint of the study is the Overall Response Rate (ORR) according to RECIST 1.1. and iRECIST will be used for treatment decisions. Secondary endpoints include OS and Progression Free Survival (PFS). </p>\n<p><strong>About Immutep</strong></p>\n<p>Further information can be found on the Company’s website www.immutep.com or by contacting:</p>\n<p><strong>Australian Investors/Media:</strong><br/>Catherine Strong, Citadel-MAGNUS<br/>+61 (0)406 759 268; cstrong@citadelmagnus.com</p>\n<p><strong>U.S. Media:</strong><br/>Tim McCarthy, LifeSci Advisors<br/>+1 (212) 915.2564; tim@lifesciadvisors.com</p>\n<p>This announcement was authorised for release by the Board of Immutep Limited. </p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/3a3b6280-4dae-4498-8cc0-c18412e47834\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 20:00 GMT+8 <a href=https://finance.yahoo.com/news/immutep-receives-fda-irb-approval-120000036.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sydney, July 06, 2021 (GLOBE NEWSWIRE) -- ASX/Media Release\n\nRegulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval received in the United States ...</p>\n\n<a href=\"https://finance.yahoo.com/news/immutep-receives-fda-irb-approval-120000036.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/.3f5AAoKp26UkGyyKEjXVQ--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","relate_stocks":{"IMM.AU":"IMMUTEP LTD","IMMP":"Immutep Limited"},"source_url":"https://finance.yahoo.com/news/immutep-receives-fda-irb-approval-120000036.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149350420","content_text":"Sydney, July 06, 2021 (GLOBE NEWSWIRE) -- ASX/Media Release\n\nRegulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval received in the United States to commence TACTI-003\nPatient recruitment into the trial is expected to begin within this quarter with European and Australian sites expected to follow\n\nImmutep Limited (ASX: IMM; NASDAQ: IMMP) (\"Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces it has completed all the necessary competent authority steps with the US Food and Drug Administration (FDA) and has received IRB approval to commence its phase IIb TACTI-003 trial in the United States. Patient recruitment for the TACTI-003 trial is expected to begin within this quarter.\nTACTI-003 will evaluate the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”), in combination with MSD’s KEYTRUDA® (pembrolizumab) as a first line therapy in approximately 154 patients with Head and Neck Squamous Cell Carcinoma (HNSCC). It is a randomised, controlled clinical study that will take place across Australia, Europe and the United States of America in up to 35 clinical sites. \nImmutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021. \nPending approval by the European and Australian competent authorities and ethics committees, Immutep expects to broaden its recruitment sites into these regions. Commenting on the start of the TACTI-003 trial, Immutep CSO and CMO Frédéric Triebel said: “We are delighted to start our new TACTI-003 trial in 1st line HNSCC patients to evaluate efti in combination with pembrolizumab vs pembrolizumab monotherapy. Results we reported from this therapeutic combination earlier in June at ASCO in the 2nd line setting were robust, with sustained and durable responses. We look forward to deepening these results with a larger group of 1st line HNSCC patients in TACTI-003.” \nAbout TACTI-003TACTI-003 is a Phase IIb clinical trial in 1st line Head and Neck Squamous Cell Carcinoma (HNSCC). It will evaluate efti in combination with MSD’s KEYTRUDA® (pembrolizumab) as a first line therapy in unresectable recurrent or metastatic HNSCC patients with PD-L1 negative and PD-L1 positive (CPS ≥1) tumors. It will be a randomised, controlled clinical study in approximately 154 first line HNSCC patients and will take place across Australia, Europe and the United States of America in up to 35 clinical sites. \nThe study will evaluate the safety and efficacy of efti in combination with pembrolizumab, compared to pembrolizumab alone in 1st line metastatic or recurrent HNSCC patients with PD-L1 positive (CPS ≥1) tumors (cohort A), and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors (CPS <1) (cohort B). According to the current plans, about 130 patients in cohort A will be randomised 1:1 to receive either efti plus pembrolizumab or pembrolizumab alone. Subjects in cohort B (up to 24 patients) will receive a combination of efti and pembrolizumab. \nThe primary endpoint of the study is the Overall Response Rate (ORR) according to RECIST 1.1. and iRECIST will be used for treatment decisions. Secondary endpoints include OS and Progression Free Survival (PFS). \nAbout Immutep\nFurther information can be found on the Company’s website www.immutep.com or by contacting:\nAustralian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com\nU.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com\nThis announcement was authorised for release by the Board of Immutep Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":94,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/157235621"}
精彩评论